Investigation Opened on Behalf of Hims & Hers Health, Inc. (HIMS) Shareholders - Contact Levi & Korsinsky
NEW YORK, NY /ACCESS Newswire / June 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Hims & Hers Health, Inc. ("Hims & Hers Health, Inc.") (NYSE:HIMS) concerning possible violations of federal securities laws.
On June 23, 2025, Novo Nordisk announced it terminated its partnership with HIMS on concerns of "illegal mass compounding and deceptive marketing." In its press release, Novo claimed HIMS "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization ' and are disseminating deceptive marketing that put patient safety at risk." As a result of the termination of the partnership, "direct access to Wegovy will no longer be available to Hims & Hers Health, Inc. via NovoCare Pharmacy.
Following this news, HIMS ' stock price fell by $16.97 per share to open at $47.25 per share.
To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY:Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services ' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE:Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
© 2025 ACCESS Newswire. All Rights Reserved.
